ORKA
Oruka Therapeutics, Inc.
A clinical-stage biotech developing longer-lasting antibody drugs for skin conditions like psoriasis, aiming for injections that may be needed only once or twice a year. Its lead candidates, ORKA-001 and ORKA-002, come from Paragon Therapeutics, a drug-discovery engine that also spawned other biotechs. The name blends Hebrew words for "skin" and "restoration," and the company went public in 2024 through a reverse merger with ARCA biopharma, trading as "ORKA."
CUSIP: 687604108HealthcareUS1 holder
Total Value
$143.09M
Total Shares
1.50M
Net Share Change
-1.16M
Activity
1 selling
Investor
Value
Shares
Weight
Change
